AC Immune SA (ACIU) vs Alpha Cognition (ACOG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Alpha Cognition (ACOG) has outperformed AC Immune SA (ACIU) over the past year, gaining 20.4% versus a loss of 17.6%. AC Immune SA is the larger company by market cap ($237.6 million vs $178.4 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACIU | ACOG |
|---|---|---|
| Share price | $2.39 | $8.19 |
| Market cap | $237.63M | $178.36M |
| 1-day change | -2.45% | -3.08% |
| YTD return | -23.89% | +26.00% |
| 1-year return | -17.59% | +20.44% |
| 5-year return | -60.36% | — |
| Forward P/E | 3.98 | — |
| EPS (TTM) | $-0.54 | $-1.32 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $10.22M |
| Net income (latest FY) | — | $-20.67M |
| Gross margin | — | 94.10% |
| Operating margin | — | -221.72% |
| Net margin | — | -202.24% |
| 52-week high | $4.00 | $10.14 |
| 52-week low | $2.10 | $4.50 |
| Distance from 52-week high | -40.25% | -19.23% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +261.51% | +119.78% |
| Average volume | 198.18K | 127.06K |
| Shares outstanding | 99.43M | 21.78M |
| Employees | 90 | 71 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACOG has outperformed ACIU by 38.0 percentage points over the past year.
About AC Immune SA
ACIU stock →AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Healthcare · Biotechnology · 90 employees
About Alpha Cognition
ACOG stock →Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease.
Healthcare · Biotechnology · 71 employees
ACIU vs ACOG FAQ
Which is bigger, AC Immune SA or Alpha Cognition?
AC Immune SA (ACIU) is larger, with a market capitalization of $237.63M compared with $178.36M for Alpha Cognition (ACOG).
Which stock has performed better over the past year, ACIU or ACOG?
ACOG returned +20.44% over the past 12 months, compared with -17.59% for ACIU (price return, excluding dividends). Past performance does not predict future results.
Are AC Immune SA and Alpha Cognition in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.